Výsledky vyhledávání - "Henry Eriksson"

Akademický článek

Warfarin intake in relation to diagnosis reduces mortality in patients with colorectal cancer – a register-based study

Autor: Anders S. Eriksson, Henry Eriksson, Per-Olof Hansson, Kurt Svärdsudd

Publikováno v: Cancer Treatment and Research Communications, Vol 40, Iss , Pp 100820- (2024)

Background: Several studies have analyzed the effect of anticoagulants on cancer survival, with varying results. This study aimed to assess the effect of warfarin on survival in patients with colorectal cancer (CRC) in relation to timing of warfarin

Externí odkaz: https://doaj.org/article/c3c268e88e0344e2bc13fe0c906da12a

Zobrazit plný text záznamu

Akademický článek

Autor: Annika Bardel, Mari-Ann Wallander, Thorne Wallman, Annika Rosengren, Saga Johansson, Henry Eriksson, Kurt Svärdsudd

Publikováno v: PLoS ONE, Vol 14, Iss 2, p e0211532 (2019)

OBJECTIVE:To study age and sex specific prevalence of 30 symptoms in random samples from the general population and to analyze possible secular trends across time. STUDY POPULATION:The study was based on data from eight on-going Swedish cohort studie

Externí odkaz: https://doaj.org/article/e85bf61a391c4991898064516ddd9cca

Zobrazit plný text záznamu

Plný text ve formátu HTML

Laboratory measurement method for the mechanical interaction between a tactile sensor and a cartonboard package – presentation and evaluation

Autor: Daniel Eriksson, Tore Käck, Camilla Persson, Henry Eriksson, Christer Korin

The importance of sensory information in product purchasing decisions has gained increasing attention in recent years. Tactile properties of packaging are usually measured with the help of trained evaluators. An objective, fast and repeatable method

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea61660f02aa57c923cc33aec69ae282
http://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-89907

Zobrazit plný text záznamu

Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RE-COVER study patients

Autor: Sam Schulman, Henry Eriksson, Waleed Ghanima, Susan R. Kahn, David R. Morrison, Per Morten Sandset, Hilde Skuterud Wik

Background Studies suggest that the direct factor Xa inhibitor rivaroxaban compared to warfarin reduces the risk of post-thrombotic syndrome (PTS) after deep vein thrombosis (DVT), but this has not been evaluated for oral direct thrombin inhibitors.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d330e1937808979233e3f7431eab325
http://hdl.handle.net/10852/90220

Zobrazit plný text záznamu

Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER®, RE-COVER™ II, and RE-MEDY™

Autor: Samuel Z. Goldhaber, Stefan Hantel, Ajay J. Kakkar, Sebastian Schellong, Henry Eriksson, Elke Schueler, Sam Schulman, Jörg Kreuzer, Martin Feuring

Publikováno v: Journal of Thrombosis and Thrombolysis. 43:484-489

The direct oral anticoagulants, e.g., dabigatran etexilate (DE), are effective and well tolerated treatments for venous thromboembolism (VTE). Net clinical benefit (NCB) is a useful concept in weighing potential benefits against potential harm of com

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::74da6423257793962a8e925ab8612ad2
https://doi.org/10.1007/s11239-017-1479-z

Zobrazit plný text záznamu

Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II

Autor: Ajay K. Kakkar, Samuel Z. Goldhaber, Sebastian Schellong, Henry Eriksson, Elke Schüler, Martin Feuring, Sam Schulman, Jörg Kreuzer, Mandy Fraessdorf

Publikováno v: Thrombosis and Haemostasis. 117:2045-2052

Management of acute venous thromboembolism (VTE) with anticoagulants in elderly patients and those with chronic kidney disease poses special challenges. The RE-COVER and RE-COVER II trials showed that dabigatran 150 mg twice daily was as effective as

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74e4196c3159f021d128738fb1b9c393
https://doi.org/10.1160/th17-03-0176

Zobrazit plný text záznamu

Bleeding events with dabigatran or warfarin in patients with venous thromboembolism

Autor: Martin Feuring, Sebastian Schellong, Clive Kearon, Jeffrey S. Friedman, Stephan Hantel, Samuel Z. Goldhaber, Henry Eriksson, Ajay K. Kakkar, Sam Schulman, Jörg Kreuzer, Ammar Majeed

Publikováno v: Thrombosis and Haemostasis. 115:291-298

SummaryDabigatran was as effective as warfarin for the acute treatment of venous thromboembolism in the RE-COVER and RE-COVER II trials. We compared the incidence of bleeding with dabigatran versus warfarin in pooled data from these studies. The loca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8991ca1251d5625134e2edec8b702cf2
https://doi.org/10.1160/th15-04-0319

Zobrazit plný text záznamu

Treatment of acute pulmonary embolism with dabigatran versus warfarin

Autor: Samuel Z. Goldhaber, Sam Schulman, Martin Feuring, Henry Eriksson, Mandy Fraessdorf, Sebastian Schellong, Joerg Kreuzer, Ajay K. Kakkar

Publikováno v: Thrombosis and Haemostasis. 116:714-721

SummaryDabigatran was non-inferior to warfarin for prevention of recurrent venous thromboembolism (VTE), and dabigatran had a lower rate of bleeding compared with warfarin in two large-scale randomised trials, RE-COVER and RE-COVER II. In this study,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0c99943a9ae2021f17defef56a21f41
https://doi.org/10.1160/th16-04-0271

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání